Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases

Brief Title

Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases

Official Title

Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases

Brief Summary

      The aim of this study is the identification of familial congenital arrhythmogenic disorders
      and their clinical follow-up.
    

Detailed Description

      Molecular genetic screening in patients with:

        -  supraventricular

        -  ventricular arrhythmia

        -  syncopes of unknown origin and/or suspicion of an arrhythmogenic origin

        -  family members of patients with sudden cardiac death and aborted sudden cardiac death

      Examination of patients includes routine testing like electrocardiogram (ECG), sequential
      ECGs, exercise testing, invasive electrophysiological stimulation, cardiac magnetic resonance
      imaging, intravenous drug challenge for identification/exclusion of eg Brugada syndrome.
      Examples are patients with Long QT Syndrome, Short QT Syndrome, Brugada Syndrome, familial
      atrial fibrillation, WPW-syndrome, arrhythmias due to familial hypertrophic cardiomyopathy or
      arrhythmogenic right ventricular dysplasia. Blood samples are taken for further molecular
      genetic screening.
    


Study Type

Observational




Condition

Long QT Syndrome



Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

300

Start Date

October 2003

Completion Date

December 2011


Eligibility Criteria

        Inclusion Criteria:

          -  Patients with a history of syncope, abnormal ECG and suspicion of an arrhythmogenic
             disease

          -  Patients with long QT syndrome

          -  Patients with short QT syndrome, shortened QT intervals, borderline shortened QT
             intervals

          -  Patients with Brugada syndrome

          -  Patients with hypertrophic cardiomyopathy

          -  Patients with arrhythmogenic right ventricular dysplasia

        Exclusion Criteria:

          -  Inability to understand study protocol
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Martin Borggrefe, Prof., MD, +49-621-383-2206, [email protected]

Location Countries

Germany

Location Countries

Germany

Administrative Informations


NCT ID

NCT00221832

Organization ID

0261.5



Study Sponsor

Heidelberg University


Study Sponsor

Martin Borggrefe, Prof., MD, Study Director, I. Department of Medicine-Cardiology


Verification Date

October 2003